Advancing Access to Clinical Trials for Cardiomyopathy

Advancing access to clinical trials for cardiomyopathy

Despite scientific advances in cardiovascular care, people living in rural areas and other communities with long-term economic or social challenges still face barriers to cutting-edge therapies such as gene editing, according to a 2020 American Heart Association presidential advisory.

Dapagliflozin enhances systolic and diastolic function in concordance with clinical response in patients with left ventricular dysfunction

OBJECTIVE: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have reshaped heart failure (HF) management. However, evidence regarding their effects on

Expanding Clinical Trial Access for Cardiomyopathy Patients

In the rapidly evolving landscape of cardiovascular medicine, transformative therapies such as gene editing have emerged as promising avenues to combat some of the most challenging heart conditions. Nevertheless, despite significant scientific advances, a disturbing disparity remains: individuals residing in rural regions or communities burdened by persistent economic and social hardships frequently encounter barriers that limit their access to …

AHA Looks to Advance Access to Clinical Trials for Cardiomyopathy

AHA initiative aims to improve education and outreach in clinical trials for progressive, often undiagnosed cardiomyopathy.